Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 7/20 | 0.61 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 3/20 | 0.55 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16460859 | 0.85 | KCNQ3 (0.64) | VNN1CES2CES1STSKCNQ3 | |
| SCHEMBL4823687 | 0.83 | CES2 (0.77) | CES2CES1STSPARP1CNR2 | |
| SCHEMBL31414638 | 0.83 | CES2 (0.77) | CES2CES1STSPARP1CNR2 | |
| Hydrochloric Acid SCHEMBL27733557 | 0.82 | CES2 (0.74) | CES2CES1STSPARP1CNR2 | |
| SCHEMBL11381382 | 0.81 | NPC1 (0.64) | CES2CES1STSPARP1CNR2 | |
| SCHEMBL15646620 | 0.81 | ABL1 (0.59) | VNN1CES2CES1STSPARP1 | |
| SCHEMBL9278411 | 0.80 | HPGD (0.69) | CES2CES1STSPARP1MEN1 | |
| SCHEMBL18286226 | 0.80 | VNN1 (0.58) | VNN1KCNQ3KCNQ2PARP1CNR2 | |
| SCHEMBL27804846 | 0.79 | STS (0.56) | VNN1CES2CES1STSPARP1 | |
| SCHEMBL755443 | 0.79 | MEN1 (0.69) | VNN1CES2CES1STSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-3303303-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | Pfizer Inc (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193844-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016193844-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | VNN1, VAT1, CMA1 | VNN1 1/4885CES2 94/4885CES1 25/4885 |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | VNN1, MVD, VAT1 | VNN1 1/4885CES2 87/4885CES1 39/4885 |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | VNN1, CMA1, VAT1 | VNN1 1/4885CES2 122/4885CES1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.